Ablevia

Executive Summary

Ablevia is a Vienna-based preclinical biotechnology company developing a proprietary small molecule platform for selective antibody removal. The platform targets undesired antibodies in autoimmune diseases, transplant rejection, and anti-drug antibody responses, offering a potential alternative to broad immunosuppression. Founded in 2018, the company leverages its unique technology to address significant unmet needs in immunology and transplantation medicine. Currently in the preclinical stage, Ablevia is advancing its lead candidates towards IND-enabling studies. The company's innovative approach could enable safer and more effective management of antibody-mediated pathologies. While still early-stage, Ablevia's platform has attracted interest from potential partners and investors. Key risks include translational uncertainty and competition from established antibody removal technologies. The company's progress in securing funding and advancing its pipeline will be critical in the near term.

Upcoming Catalysts (preview)

• H2 2026Series A Financing Round70% success
• H1 2027First IND Filing40% success
• H2 2026Research Collaboration Partner60% success